Down Syndrome and Alzheimer's Disease: A Family Guide

Summary: People with Down syndrome have approximately an 80 percent lifetime risk of Alzheimer's disease, driven by an extra copy of the amyloid precursor protein (APP) gene on chromosome 21. Brain changes begin in adolescence; clinical dementia typically develops 20-30 years earlier than in the general population. Routine baseline cognitive screening should start at age 30, every two years through the 40s, and annually from age 50 — per the 2025 British Psychological Society/Royal College of Psychiatrists joint guidelines.

People with Down syndrome have an exceptionally high lifetime risk of Alzheimer's disease — higher than any other identifiable population. By age 40, nearly every person with Down syndrome shows the brain changes of Alzheimer's disease on autopsy or imaging, even before any cognitive symptoms appear. By 60, the majority have clinical dementia. By the end of normal life expectancy in Down syndrome — now into the 60s and beyond, thanks to dramatic improvements in cardiac and medical care over recent decades — lifetime Alzheimer's risk is estimated at around 80 percent.

This is essentially a genetic form of Alzheimer's disease, written into the chromosomes from birth. And yet many families of adults with Down syndrome aren't told about this risk until symptoms have already begun. This article is a physician's guide to what Down syndrome-associated Alzheimer's is, what families and caregivers can do, and what current research suggests for the future.

Content draws on the audit of dementia screening pathways in adult learning disability services presented at the American Psychiatric Association 2026 Annual Meeting, along with the broader clinical literature.

Why Down syndrome and Alzheimer's are biologically linked

Down syndrome is caused by trisomy 21 — the presence of three copies of chromosome 21 instead of the typical two. Chromosome 21 carries hundreds of genes, but one of them turns out to be particularly important for Alzheimer's risk: the amyloid precursor protein (APP) gene.

APP produces the precursor protein from which beta-amyloid is cleaved. Beta-amyloid is the protein that accumulates in plaques in the brains of people with Alzheimer's disease. Having three copies of chromosome 21 means producing about 50 percent more APP from birth, and lifelong overproduction of beta-amyloid leads to progressive amyloid accumulation in the brain over decades.

The resulting pathology — amyloid plaques and neurofibrillary tangles made of tau protein — is biologically the same as the pathology of typical late-onset Alzheimer's disease. The difference is the timeline: brain changes begin in childhood and adolescence, become widespread by the 30s, and reach the levels associated with clinical dementia decades earlier than in the general population.

A small subset of families with autosomal dominant Alzheimer's disease (in which a duplication of just the APP gene region is inherited without the full trisomy) have similar early-onset Alzheimer's — confirming that the APP gene dosage is what's driving the risk.

The numbers

Estimates vary somewhat between studies, but the consistent picture is:

• By age 30-40: Brain amyloid pathology is present in essentially everyone with Down syndrome, though most are not clinically demented yet
• By age 50: Roughly 25-30 percent have clinical Alzheimer's dementia
• By age 60: Roughly 50-70 percent have clinical Alzheimer's dementia
• Lifetime risk: Approximately 80 percent develop clinical Alzheimer's disease

For context, the lifetime Alzheimer's risk in the general population is roughly 10-20 percent depending on demographics. Down syndrome multiplies that risk severalfold and shifts it 20-30 years earlier.

Life expectancy in Down syndrome has improved dramatically over recent decades — from roughly 25 years in the 1980s to 60+ years now in well-resourced healthcare systems. This is a major medical success, but it means that more people with Down syndrome are now living long enough to develop the Alzheimer's disease that has always been written into their biology. The clinical challenge of recognizing, diagnosing, and supporting these patients and their families is therefore growing.

Why screening matters specifically in Down syndrome

The recent audit at Your Healthcare CIC (presented at APA 2026 by Challen, Melrose, and Patel) found that despite published guidelines recommending routine baseline screening, only 14 of 26 patients in their dementia pathway had any evidence of baseline cognitive assessment, and no baseline assessments had been undertaken since 2015. Most referrals were symptomatic — meaning the dementia process had already progressed before evaluation. Average time on the screening pathway was 15.8 months, suggesting delays from initial concern to diagnosis.

This pattern is widely reported. The reasons screening is critical in Down syndrome but often missed:

The baseline problem

People with Down syndrome have lifelong intellectual disability of varying degrees. Cognitive testing like the MMSE or MoCA, designed for the general population, often produces low scores even in people with stable, unchanged cognitive function. Comparing a 50-year-old with Down syndrome to general population norms tells you nothing useful about whether dementia is developing. What matters is comparing them to themselves.

Without a baseline assessment done before symptoms appear, clinicians have no reference point. Subtle early changes — losing previously mastered skills, becoming more dependent, behavioral shifts — get attributed to "just getting older" or "being a bit different lately" when in fact they represent early Alzheimer's.

The screening guidelines

The 2025 British Psychological Society and Royal College of Psychiatrists national guidelines recommend:

• Age 30: Baseline cognitive and functional assessment
• 40s: Reassessment every 2 years
• 50+: Annual reassessment

The U.S. National Task Group on Intellectual Disabilities and Dementia Practices (NTG) and the American Academy of Neurology have similar recommendations. The American Association on Intellectual and Developmental Disabilities supports proactive screening starting in the 30s.

The specific tools

Several cognitive assessment tools have been developed specifically for use in intellectual disability and Down syndrome:

• CAMDEX-DS (Cambridge Examination for Mental Disorders of Older People with Down's Syndrome) — comprehensive structured assessment
• DMR / DSQIID (Dementia Questionnaire for People with Intellectual Disabilities) — informant-rated questionnaire completed by caregivers
• NTG-EDSD (NTG Early Detection Screen for Dementia) — screening tool for intellectual disability populations
• DLD (Dementia Scale for Down Syndrome) — informant-rated screening tool
• OMQ (Object Memory Questionnaire) — patient-administered memory test

Standard tools like the Mini-Mental State Examination, the clock drawing test, and the MoCA are sometimes used adjunctively, but interpretation requires significant adjustment for baseline intellectual function. A clinician experienced with Down syndrome and intellectual disability should be involved.

How Alzheimer's presents in Down syndrome

Early signs in this population are often different from the classic memory complaints of late-onset Alzheimer's. Because many people with Down syndrome have lifelong differences in memory, language, and executive function, the changes that signal dementia are more often functional and behavioral.

Common early signs

• Loss of previously mastered skills — needing more help with dressing, hygiene, or routine tasks the person had done independently for years
• Decline at work or in day programs — slowness, errors, or loss of skills in a sheltered work or day-program setting
• Behavioral changes — increased apathy, irritability, anxiety, or social withdrawal
• Sleep changes — increased daytime sleeping, nighttime disturbance
• Seizures — new-onset seizures in adults with Down syndrome can be an early sign of Alzheimer's disease, far more common in this population than in typical AD
• Gait changes — slowness, shuffling, falls
• Incontinence — a new and often overlooked sign
• Hearing things or visual hallucinations — sometimes
• Forgetting names and recent events — present but often less prominent than functional changes early
• Disorientation — getting lost in familiar settings, confusion about time of day

How families typically notice

Because the person may have lifelong language and communication differences, the earliest signals are usually noticed by the people who know the person best — parents, siblings, day-program staff, group home staff. Often what's noticed first is "she's just not the same lately." Specific things to ask:

• Has she stopped doing tasks she used to do?
• Has there been new behavior — agitation, withdrawal, mood changes?
• Has she become disoriented or confused in familiar places?
• Is she sleeping differently?
• Are there any new physical changes — gait, balance, incontinence?

These observations are clinically valuable. Bring specific examples and dates to the medical appointment.

Reversible contributors — rule these out first

Before attributing changes to Alzheimer's disease, evaluate and treat reversible conditions that can mimic dementia in this population:

Hypothyroidism

People with Down syndrome have a very high rate of thyroid disease — both hypothyroidism (most common) and hyperthyroidism. Hypothyroidism causes fatigue, slowed thinking, weight gain, and apparent cognitive decline. Annual thyroid screening is standard care in Down syndrome, but it's often the first thing to check when new symptoms emerge.

Sleep apnea

Sleep apnea is extremely common in Down syndrome — affecting perhaps 50-80 percent of adults. Untreated sleep apnea causes daytime cognitive symptoms that can mimic dementia. Treatment with CPAP, in patients who can tolerate it, often substantially improves daytime function. See our sleep and dementia risk post.

Depression

Late-life depression in people with Down syndrome can look very much like dementia — apathy, slowed thinking, withdrawal, sleep disruption. The distinction matters because depression is treatable. See our depression vs dementia post.

Vision and hearing loss

Both are common in Down syndrome and worsen with age. Uncorrected sensory deficits cause withdrawal, confusion, and apparent cognitive decline. Annual vision and hearing screening should be standard.

Vitamin deficiencies

B12 deficiency is more common in Down syndrome. Check levels and correct if low.

Medication effects

Many medications used for psychiatric or behavioral symptoms in intellectual disability — antipsychotics, anticholinergics, benzodiazepines — can cause cognitive side effects that mimic dementia. A medication review is part of any cognitive evaluation.

Acute illness

Urinary tract infections, pneumonia, dehydration, and other acute illnesses can cause delirium that looks like dementia. Sudden onset of confusion (hours to days) is delirium until proven otherwise and warrants urgent medical evaluation.

Diagnosis: what a good workup looks like

A proper diagnostic workup for suspected Alzheimer's in a person with Down syndrome includes:

1. A detailed history from the person, family members, and any day-program or group home staff who know them well
2. Review of baseline cognitive function — if available — and comparison to current
3. Functional assessment — specifically what the person can do now versus what they could do 1, 2, 5 years ago
4. Physical and neurological exam
5. Cognitive testing with tools appropriate to intellectual disability (CAMDEX-DS, DMR, NTG-EDSD)
6. Blood work: thyroid function, B12, folate, comprehensive metabolic panel, CBC, vitamin D
7. Evaluation for treatable contributors: sleep apnea, depression, sensory deficits, medication effects
8. Brain imaging (MRI) when appropriate — particularly to rule out other causes (stroke, hydrocephalus, mass lesions)
9. EEG if seizures are part of the presentation
10. Referral to a specialist familiar with both Down syndrome and dementia — typically a geriatric psychiatrist or a memory clinic with intellectual disability experience

Average time from initial concern to formal diagnosis in this population is often well over a year. Streamlining this pathway is a key goal of services that audit themselves against the published guidelines.

What treatment looks like

The treatment landscape for Alzheimer's disease in Down syndrome partly overlaps with general AD treatment and partly differs.

Cholinesterase inhibitors and memantine

Donepezil, rivastigmine, galantamine, and memantine — the medications used for typical late-onset Alzheimer's — are sometimes used off-label in Down syndrome-associated AD. Evidence in this population is more limited than in the general AD population, and individual response varies. A specialist familiar with this population is the right person to weigh whether to try them and how to monitor.

Anti-amyloid antibodies (lecanemab, donanemab)

These newer disease-modifying medications were approved based on trials in late-onset Alzheimer's and did not specifically include people with Down syndrome. As of 2026, their use in Down syndrome-associated AD remains an active question. The underlying biology — amyloid pathology — is the same, suggesting these medications could theoretically work in this population. Specific safety considerations, including the risk of ARIA (amyloid-related imaging abnormalities), need to be carefully weighed by specialists. Clinical trials specifically in Down syndrome are ongoing.

See our lecanemab and donanemab patient guide for general background on these medications.

Behavioral and environmental support

Often the most important component of treatment is non-pharmacological:

• Consistent routines and environments
• Familiar caregivers
• Sensory support — corrected vision and hearing, comfortable lighting, reduced overstimulation
• Meaningful activities matched to current ability
• Support for caregivers and families
• Day programs adapted to dementia needs

Managing co-occurring conditions

Sleep apnea treatment, thyroid management, treatment of depression, and management of seizures (when present) all affect overall function and quality of life. Comprehensive medical care is the foundation.

Planning ahead

A Down syndrome diagnosis combined with the high risk of Alzheimer's means that families and care teams should plan proactively — not after symptoms appear.

In the 20s and 30s

• Establish a primary care relationship with a clinician experienced in Down syndrome
• Baseline cognitive assessment by age 30
• Establish baseline cognitive testing tools that can be repeated over time
• Maintain regular medical care: annual physicals, vision and hearing, dental, thyroid screening, sleep apnea evaluation if symptoms present

In the 40s

• Cognitive reassessment every 2 years
• Discuss the increased Alzheimer's risk explicitly with the person (in age-appropriate language) and family
• Update legal documents: power of attorney, healthcare proxy, supported decision-making arrangements
• Identify a dementia-capable clinician if not already in place
• Plan financially for potentially complex care needs

In the 50s and beyond

• Annual cognitive reassessment
• Lower threshold for evaluating new symptoms
• Connect with dementia-specific resources including the NTG, Alzheimer's Association, National Down Syndrome Society
• Plan for care setting changes as needs evolve
• Family education about what to expect

Specific resources

• NTG (National Task Group on Intellectual Disabilities and Dementia Practices) — practice guidelines, screening tools, family resources
• National Down Syndrome Society (NDSS) — has Alzheimer's disease information and family support
• Alzheimer's Association — particularly local chapters that have intellectual disability programs
• DSC (Down Syndrome International) — global perspective and resources
• LuMind IDSC Foundation — research and clinical resources

Caring for siblings and family caregivers

A specific note for families: when an adult with Down syndrome develops Alzheimer's disease, the caregiving role often falls to aging parents or to a sibling who may already have their own family and career. The emotional and practical complexity is real.

• Anticipatory grief is common — and the caregiver may be losing a sibling or adult child they've cared for for decades. See our anticipatory grief post.
• Caregiver burnout is common in this population — see our caregiver burnout post.
• Sibling-specific support is sometimes available through Down syndrome organizations
• Respite care options should be identified before they're needed
• Long-term care planning is essential — many group home and memory care settings are not equipped to handle the combination of intellectual disability and dementia

A note on dignity and personhood

People with Down syndrome who develop Alzheimer's disease are often misunderstood by clinicians and care systems unfamiliar with intellectual disability. Some practical observations:

• The person's lifelong personality, preferences, and relationships remain part of who they are — these are not erased by dementia
• Communication may have always been different — adapting to the person's communication style is essential
• Decisions about care should involve the person to the maximum extent possible, with support tailored to their abilities
• Behavioral changes are often communicating something — pain, confusion, fear, unmet needs — even when the person can't verbalize it
• The right care team treats the person as a whole human being with intellectual disability and dementia, not just a "case" of either

Down syndrome organizations have increasingly emphasized that dignity, agency, and personhood are central to good care across the lifespan — including when Alzheimer's disease is part of the picture.

Closing

Down syndrome and Alzheimer's disease are biologically linked through the chromosome 21 origin of the amyloid precursor protein. The high lifetime risk, the earlier onset, and the unique challenges of recognizing dementia in someone with lifelong intellectual disability all mean that families benefit from being informed proactively rather than reactively.

Routine baseline cognitive screening starting in the late 20s or early 30s, annual screening from age 50, attention to reversible contributors like sleep apnea and thyroid disease, and connection with specialists experienced in this specific population are the foundations of good care. The newer disease-modifying medications may eventually have a role in this population, but as of 2026 their use here is still being studied.

The person with Down syndrome is still the person they have always been. The medical, behavioral, and emotional support — for them and for their family — needs to honor that.

Related reading

• Alzheimer's Disease: A Complete Guide
• Dementia Diagnosis Appointment: What to Expect
• Sleep and Dementia Risk
• Depression vs Dementia in Older Adults
• Caregiver Burnout in Dementia
• Anticipatory Grief in Dementia
• Lecanemab and Donanemab: A Patient's Guide

References

• Challen C, Melrose Z, Patel R. An audit of the dementia screening pathway in a community adult learning disability service: Your Healthcare CIC Kingston & Richmond. American Psychiatric Association 2026 Annual Meeting, San Francisco.
• British Psychological Society and Royal College of Psychiatrists. Dementia and People with Intellectual Disabilities: Guidance on the Assessment, Diagnosis, Interventions and Support of People with Intellectual Disabilities Who Develop Dementia. 2025 update.
• McCarron M, McCallion P, Reilly E, et al. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. Journal of Intellectual Disability Research. 2017;61(9):843-852.
• Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down's syndrome. Lancet Neurology. 2016;15(6):622-636.
• Fortea J, Vilaplana E, Carmona-Iragui M, et al. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. The Lancet. 2020;395(10242):1988-1997.
• National Task Group on Intellectual Disabilities and Dementia Practices. NTG-EDSD: NTG Early Detection Screen for Dementia. (current version).
• Strydom A, Coppus A, Blesa R, et al. Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2018;4:703-713.

---

Disclosure: Dr. Shimada is the founder of Tokei Health. This article is informational and is not a substitute for individual medical advice from your own clinician. Care decisions for individuals with Down syndrome and suspected or confirmed Alzheimer's disease should be made with clinicians experienced in both intellectual disability and dementia care.